Heron Therapeutics (HRTX) AI Stock Analysis

Compare

1,637 Followers

Top Page

Heron Therapeutics

(NASDAQ:HRTX)

Select Model

Neutral 48 (OpenAI - 5.2)

Rating:48Neutral

Price Target:

$1.00

▼(-15.97% Downside)

Action:ReiteratedDate:02/27/26

The score is held back primarily by balance-sheet leverage and ongoing negative operating/free cash flow, despite meaningful profitability improvement. Technicals are also bearish (below key moving averages with negative MACD). Offsetting these, the latest earnings call was supportive with EBITDA-positive guidance and clear Acute Care momentum, but risks (Oncology decline, pricing pressure, multi-year PFS timeline, litigation) keep the overall score below average.

Positive Factors

Acute Care Commercial Momentum

Sustained, outsized growth in Acute Care (ZYNRELEF and APONVIE) with quarter-over-quarter acceleration and product-specific J-codes indicates durable commercial adoption in hospitals. Reimbursement clarity and workflow simplifications reduce adoption friction, supporting predictable, scalable sales over 2–6 months.

High Gross Margins and Profitability Improvement

A ~72–73% gross margin and a sharp narrowing of losses with EBIT near breakeven reflect favorable product economics and improving operational leverage. This margin profile supports funding commercial expansion and reduces the magnitude of external capital required as revenues scale.

Capital Structure Relief from Financing

Eliminating a prior capital-structure overhang via 2025 financing materially reduces immediate refinancing risk and short-term dilution pressure. This provides durable optionality to invest in salesforce, reimbursement efforts, and commercial programs that can materially improve revenue and cash generation going forward.

Negative Factors

Elevated Financial Leverage

Very high leverage versus a thin equity base leaves the company financially fragile: lower flexibility for strategic investments, higher refinancing and covenant risk, and greater sensitivity to any decline in cash flow. Even with some debt reduction, capitalization remains tight for biotech volatility.

Negative Operating and Free Cash Flow

Persistent negative operating and free cash flows mean the business is not yet self-funding. Continued reliance on external capital or strong commercial ramp is required to fund growth; absent sustained improvement, cash shortfalls could force dilution or restrict investment in commercialization.

Oncology Franchise Headwinds

A planned wind-down of SUSTOL and expected pricing pressure on CINVANTI reduce a sizable revenue base, increasing top-line concentration risk. Combined with pending litigation and pricing erosion risks, Oncology weakness could slow aggregate revenue growth and stress cash generation until Acute Care offsets the gap.

Heron Therapeutics (HRTX) vs. SPDR S&P 500 ETF (SPY)

Market Cap

$224.36M

Dividend YieldN/A

Average Volume (3M)1.41M

Price to Earnings (P/E)―

Beta (1Y)0.92

Revenue Growth12.60%

EPS Growth58.23%

CountryUS

Employees122

SectorHealthcare

Sector Strength45

IndustryBiotechnology

Share Statistics

EPS (TTM)-0.02

Shares Outstanding188,537,140

10 Day Avg. Volume2,294,859

30 Day Avg. Volume1,408,464

Financial Highlights & Ratios

PEG Ratio-0.31

Price to Book (P/B)15.12

Price to Sales (P/S)1.40

P/FCF Ratio-7.77

Enterprise Value/Market Cap1.34

Enterprise Value/Revenue1.95

Enterprise Value/Gross Profit2.66

Enterprise Value/Ebitda-24.93

Forecast

1Y Price Target

$4.50

Price Target Upside278.15% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)-0.02

Revenue Forecast (FY)$171.73M

Heron Therapeutics Business Overview & Revenue Model

Company DescriptionHeron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

How the Company Makes MoneyHeron Therapeutics generates revenue primarily through the sales of its pharmaceutical products, particularly its branded medications. The company has established a revenue model that includes direct sales to healthcare providers and institutions, as well as distribution partnerships with wholesalers. Key revenue streams include sales from its flagship products, which are marketed directly to hospitals and clinics. Additionally, Heron may receive milestone payments and royalties from collaborations with other pharmaceutical companies as part of strategic partnerships aimed at co-developing or commercializing new therapies. The company also benefits from reimbursement agreements with insurance providers, which facilitate access to its products for patients.

Heron Therapeutics Key Performance Indicators (KPIs)

Any

Net Sales by Segment

Net Sales by Segment
Breaks down Heron’s revenue by product line, therapeutic area, or geography to show which drugs and markets are driving growth or creating concentration risk. For a company with a small commercial portfolio, segment-level sales reveal whether recent launches, pricing, and reimbursement are gaining traction, highlight dependence on any single product or region, and flag where weaker demand or payer pressure could meaningfully affect top-line growth and margins.

Chart InsightsHeron’s revenue mix is shifting from legacy SUSTOL toward its acute-care launches: ZYNRELEF and APONVIE are the fastest-growing drivers while CINVANTI remains a stable oncology anchor. Recent quarters show ZYNRELEF momentum (despite a prior reporting adjustment) and a clear ramp in APONVIE, while SUSTOL trends downward and suffered an inventory-related hit that pressured gross margin. Management’s completed financing, new sales initiatives and a permanent J-code for ZYNRELEF underpin upside, but execution and reimbursement will determine whether higher-margin growth offsets SUSTOL’s decline.

Data provided by:

The Fly

Heron Therapeutics Earnings Call Summary

Earnings Call Date:Feb 26, 2026

(Q4-2025)

% Change Since: |

Next Earnings Date:May 11, 2026

Earnings Call Sentiment Positive

The call communicated strong commercial inflection and financial progress: record annual revenue (~$155M), improved gross margin (~73%), and adjusted EBITDA of $14.7M, alongside clear Q4 momentum in Acute Care driven by ZYNRELEF (+48% YoY) and APONVIE (+97% YoY). Operational wins (financing completion, J-codes, VAN rollout, CrossLink IGNITE, guideline inclusion) support continued growth. Key risks include ongoing Oncology headwinds from the SUSTOL wind-down (7.8% YoY decline in Oncology revenue), pricing pressure and competition for CINVANTI, the multi-year timeline for ZYNRELEF PFS approval, the need to educate providers on the NOPAIN Act, and litigation uncertainty. Management expects to remain EBITDA positive in 2026 while making targeted commercial investments that may temporarily moderate near-term EBITDA but aim to accelerate longer-term revenue and value creation.

Q4-2025 Updates

Positive Updates

Record Annual Revenue and Improved Profitability

Full year 2025 net product sales of $154.9 million and adjusted EBITDA of $14.7 million (more than doubling prior year performance), beating prior guidance of $9M–$13M. Gross margin approximately 73%, reflecting improved cost discipline and favorable product mix.

Acute Care Quarter Acceleration

Acute Care net sales of $16.3 million in Q4 2025, up ~33% quarter-over-quarter from $12.3 million (Q3). The Acute Care franchise increased more than 57% year-over-year in the quarter, signaling clear momentum heading into 2026.

ZYNRELEF Strong Growth and Reimbursement Progress

ZYNRELEF Q4 net sales of $12.5 million (up from $9.3 million in Q3) and 48% year-over-year revenue growth in the quarter. Reimbursement clarity improved with permanent J-code (J0668) and workflow simplifications (VAN rollout); prefilled syringe (PFS) program progressing with potential approval targeted mid- to late-2027.

APONVIE Rapid Adoption and Guideline Inclusion

APONVIE Q4 net sales $3.8 million, up 97% year-over-year; demand units grew ~101% YoY. Included in the Fifth Consensus Guidelines for PONV and granted a permanent product-specific J-code (J8502). Dedicated hospital-focused sales team (IBM group) launched to accelerate hospital adoption.

Successful Financing and Strong Balance Sheet

Completed a financing in 2025 that eliminated a capital-structure overhang, providing financial flexibility to increase targeted commercial investments and execute growth initiatives.

Concrete 2026 Guidance with Continued Profitability Target

Management provided 2026 guidance of $173M–$183M in net product sales and adjusted EBITDA of $10M–$20M, and reiterated an expectation to remain EBITDA positive while making targeted commercial investments to accelerate growth.

Operational Initiatives Driving Commercial Execution

Implemented CrossLink IGNITE incentive program (expanded into 2026), completed VAN rollout to reduce administration friction, and leveraged permanent coding and guideline inclusion to reduce hospital adoption barriers — all cited as drivers of improved distributor/hospital execution.

Negative Updates

Oncology Franchise Pressure and SUSTOL Wind-down

Oncology franchise generated just over $105 million for full year 2025, a modest 7.8% decline versus 2024, largely attributable to the planned wind down of SUSTOL throughout 2026. Oncology Q4 net sales were $24.2 million and the decline creates a headwind to the franchise base.

CINVANTI Competitive and Pricing Dynamics

CINVANTI remains resilient in demand but faces increased competitive pressure and expected price erosion, particularly on the clinic side. Management expects unit/volume growth but some offset from pricing declines, leading to relatively flat sales in 2026 absent other drivers.

Near-Term EBITDA May Be Moderated by Increased Commercial Spend

Company plans to increase targeted commercial investments (adding field capacity midyear and prioritizing geographic expansion), which management says may temporarily moderate EBITDA growth despite longer-term return expectations.

Timing Risk for ZYNRELEF Prefilled Syringe (PFS)

PFS registration batches placed on stability in Q4 2025; product requires 12 months of stability testing plus a standard 4–6 month regulatory review, implying potential approval only in mid- to late-2027 — a multi-year timing risk for a key expansion.

Adoption Lag for NOPAIN Act and Reimbursement Education Needs

Awareness and implementation of the NOPAIN Act among providers progressed more slowly than anticipated, requiring additional education and resources; that adoption lag can delay the expected reimbursement tailwind for ZYNRELEF.

Ongoing Litigation Uncertainty (Slayback case)

Slayback litigation concerning CINVANTI is pending in the U.S. District Court of Delaware (Judge Bryson). Management expressed confidence but the outcome is uncertain; a decision is expected prior to the 30-month stay expiration, representing legal and market risk.

Company Guidance

Heron guided 2026 net product sales of $173–$183 million and adjusted EBITDA of $10–$20 million, saying it expects to remain EBITDA‑positive while making targeted commercial investments that may moderate near‑term EBITDA but accelerate revenue and free‑cash‑flow generation in 2027; this follows FY2025 results of ~$154.9–$155 million in net product sales, adjusted EBITDA of $14.7 million (above prior guidance of $9–$13M) and ~73% gross margin. Management pointed to clear Q4 momentum in Acute Care—Q4 Acute Care net sales of $16.3M (Q3 $12.3M, +33% q/q), ZYNRELEF $12.5M (+48% y/y; Q3 $9.3M) and APONVIE $3.8M (+97% y/y; demand units +101% y/y)—and Oncology net sales of $24.2M (full‑year Oncology ≈$105M, down ~7.8% y/y largely due to SUSTOL wind‑down). They also reiterated a potential mid‑ to late‑2027 approval for a ZYNRELEF prefilled syringe pending 12 months of stability testing plus a 4–6 month regulatory review.

Heron Therapeutics Financial Statement Overview

Summary

Operating performance is improving materially (gross margin ~72–73%, losses narrowed sharply and EBIT near breakeven), but fundamentals are still constrained by weak balance-sheet and cash-flow quality (high leverage vs. small equity base and negative TTM operating/free cash flow). Revenue also declined ~12.4% TTM, adding near-term top-line risk.

Income Statement

Neutral

TTM (Trailing-Twelve-Months) revenue is $154.9M, down 12.4% versus the prior year, but the company has materially improved profitability versus earlier years. Gross margin remains strong (~72% TTM), and losses have narrowed sharply (TTM net loss of ~$20.2M vs. ~$110.6M in 2023 and ~$182.0M in 2022), with EBIT close to breakeven TTM. Key weakness is that the company is still unprofitable and top-line momentum turned negative after growth in 2022–2024.

Balance Sheet

Negative

Leverage is high relative to the equity base. TTM total debt is ~$140.6M while stockholders’ equity is only ~$14.3M, implying very elevated leverage (debt-to-equity ~9.4x). Equity has also been volatile (negative in 2023–2024, positive in 2025), which adds balance-sheet risk. A positive is that total debt declined versus 2023–2024 (~$178–$180M range), but overall capitalization remains thin for the level of debt.

Cash Flow

Negative

Cash generation remains a clear pressure point. TTM operating cash flow is negative (~-$27.6M) and free cash flow is also negative (~-$27.9M), with TTM free cash flow deterioration versus the prior year. While cash burn has improved significantly from 2021–2023 levels, the business is not yet self-funding, increasing reliance on external capital or continued operational improvement.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	154.90M	144.28M	127.04M	107.67M	86.35M
Gross Profit	113.56M	105.64M	61.94M	52.80M	40.33M
EBITDA	-17.88M	-5.06M	-103.79M	-176.66M	-215.25M
Net Income	-20.20M	-13.58M	-110.56M	-182.02M	-220.68M
Balance Sheet
Total Assets	255.88M	233.15M	222.51M	250.95M	305.71M
Cash, Cash Equivalents and Short-Term Investments	46.63M	59.28M	80.41M	84.85M	157.58M
Total Debt	140.64M	177.76M	179.63M	157.48M	159.50M
Total Liabilities	241.54M	266.80M	256.48M	237.38M	228.14M
Stockholders Equity	14.33M	-33.65M	-33.97M	13.57M	77.57M
Cash Flow
Free Cash Flow	-27.91M	-24.23M	-60.33M	-148.74M	-206.38M
Operating Cash Flow	-27.59M	-22.53M	-58.79M	-146.91M	-203.35M
Investing Cash Flow	16.01M	18.71M	18.00M	-3.32M	32.73M
Financing Cash Flow	14.43M	940.00K	54.11M	75.06M	156.03M

Heron Therapeutics Technical Analysis

Technical Analysis Sentiment

Negative

Last Price1.19

Price Trends

50DMA

1.30

Negative

100DMA

1.26

Negative

200DMA

1.48

Negative

Market Momentum

MACD

-0.05

Positive

RSI

45.45

Neutral

STOCH

39.81

Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HRTX, the sentiment is Negative. The current price of 1.19 is below the 20-day moving average (MA) of 1.22, below the 50-day MA of 1.30, and below the 200-day MA of 1.48, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 45.45 is Neutral, neither overbought nor oversold. The STOCH value of 39.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HRTX.

Heron Therapeutics Risk Analysis

Heron Therapeutics disclosed 55 risk factors in its most recent earnings report. Heron Therapeutics reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added 0 New Risks

Heron Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
OCGN	54 Neutral	$596.76M	-8.40	-289.93%	―	14.26%	-23.34%
KOD	54 Neutral	$1.64B	-6.51	-207.92%	―	―	-12.93%
NMRA	52 Neutral	$583.14M	-2.39	-104.35%	―	―	20.71%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BNTC	49 Neutral	$374.46M	-11.73	-29.59%	―	―	80.95%
SGMT	49 Neutral	$177.02M	―	-39.78%	―	―	-38.23%
HRTX	48 Neutral	$224.36M	―	―	―	12.60%	58.23%

* Healthcare Sector Average

Performance Comparison

HRTX

Heron Therapeutics

1.20

-1.04

-46.43%

OCGN

Ocugen

1.94

1.34

220.66%

BNTC

Benitec Biopharma

10.83

-1.59

-12.80%

KOD

Kodiak Sciences

27.36

23.46

601.54%

SGMT

Sagimet Biosciences, Inc. Class A

5.72

2.27

65.80%

NMRA

Neumora Therapeutics, Inc.

3.20

1.80

128.57%

Heron Therapeutics Corporate Events

Business Operations and StrategyFinancial Disclosures

Heron Therapeutics Reports Strong Preliminary Q4 2025 Revenue

Positive

Jan 9, 2026

On January 9, 2026, Heron Therapeutics reported preliminary, unaudited net revenue of approximately $40.5 million for the fourth quarter ended December 31, 2025, and about $154.9 million for full-year 2025, underscoring continued momentum across its acute care and oncology supportive care portfolio. Within Q4, CINVANTI remained the largest revenue contributor at roughly $22.9 million, while ZYNRELEF generated about $12.5 million and delivered the strongest quarter-over-quarter growth in the portfolio, rising around 35% versus the third quarter, with APONVIE and SUSTOL contributing approximately $3.8 million and $1.3 million, respectively; the solid top-line performance and particularly strong uptake of ZYNRELEF highlight progress in Heron’s acute care franchise and suggest strengthening commercial execution heading into the company’s final audited results.

The most recent analyst rating on (HRTX) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Heron Therapeutics stock, see the HRTX Stock Forecast page.

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Feb 27, 2026